Global

Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

GIST Care Looks Beyond First-Generation KIT Control

Pancreatic Cancer Finally Gets a RAS Moment

What happens when surgeons no longer need to be in the same country as their patients?

EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption

As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
